Merck (NYSE: MRK) reported Q1 EPS of $1.40, $0.23 worse than the analyst estimate of $1.63. Revenue for the quarter came in at $12.1 billion versus the consensus estimate of $12.66 billion.

GUIDANCE:

Merck sees FY2021 EPS of $6.48-$6.68, versus the consensus of $6.58. Merck sees FY2021 revenue of $51.8-53.8 billion, versus the consensus of $52.51 billion.

For earnings history and earnings-related data on Merck (MRK) click here.